

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6164023

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ONCOQUEST INC.	06/09/2020
RECEIVING PARTY DATA	
Name:	ONCOQUEST PHARMACEUTICALS INC.
Street Address:	670-21 SANNAE-RO
Internal Address:	SANNAE-MYEON
City:	MIRYANG-SI
State/Country:	KOREA, REPUBLIC OF
PROPERTY NUMBERS Total: 16	
Property Type	Number
Patent Number:	6716966
Patent Number:	7147850
Patent Number:	6689355
Patent Number:	8038994
Patent Number:	6241985
Patent Number:	8945566
Patent Number:	8697079
Patent Number:	10392444
Patent Number:	10537636
Application Number:	16448453
Application Number:	62034915
Application Number:	15541451
Application Number:	62103758
Application Number:	16702323
Application Number:	62455114
Application Number:	16482163
CORRESPONDENCE DATA	
Fax Number:	(514)448-4607
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

PATENT

Phone: 5146584844
Email: mathieu@benoit-cote.com
Correspondent Name: MATHIEU MIRON
Address Line 1: 560 BOUL CREMAZIE E
Address Line 2: SUITE 300
Address Line 4: MONTREAL, CANADA H2P 1E8

ATTORNEY DOCKET NUMBER:	G2204CA00
--------------------------------	-----------

NAME OF SUBMITTER:	MATHIEU MIRON
---------------------------	---------------

SIGNATURE:	/MATHIEU MIRON/
-------------------	-----------------

DATE SIGNED:	06/22/2020
---------------------	------------

Total Attachments: 6

source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page1.tif
source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page2.tif
source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page3.tif
source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page4.tif
source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page5.tif
source=G2204CA00_Universal Assignment to Oncoquest Pharmaceuticals#page6.tif

UNIVERSAL ASSIGNMENT

WHEREAS ONCOQUEST INC., a corporation of Alberta, whose full address is 8123 Roper Road NW, Edmonton, Alberta, T6E 6S4, Canada; hereinafter referred to as the "Assignor", is the exclusive owner of the patents and patents application(s) listed in Schedule A attached hereto and any inventions disclosed therein.

AND WHEREAS ONCOQUEST PHARMACEUTICALS INC., a corporation of the Republic of Korea, whose full address is 670-21 Sannae-ro, Sannae-myeon, Miryang-Si, Republic of Korea; hereinafter referred to as the "Assignee", has acquired from the Assignor the whole right, title and interest for the United States of America, Canada and all other countries in and to the said invention and in and to any Letters Patent that may be obtained therefor, and in and to said application(s).

NOW THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt of all of which is hereby acknowledged, the Assignor, by these presents confirms to have sold, assigned and transferred and do hereby sell, assign and transfer unto the said Assignee, the full and exclusive right to the said invention in the United States of America, Canada and all other countries and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor, and the entire right, title and interest in and to said application(s), and in and to any divisions, continuations, continuations-in-part and extensions of said application(s), together with the right to claim the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property based on said patent application(s), the right to take any legal action concerning the rights granted by any such patents or patent applications including the right to sue for any past or previous infringements.

Assignor agrees that he/she will without further consideration do all such things and execute all such documents as may be necessary or desirable to obtain and maintain patents for said invention and for additions and modifications thereto in any and all countries, and to vest title thereto in said Assignee, its successors, assigns and legal representatives or nominees.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, the assignee of the entire right, title and interest in



and to the same, for its sole use and benefit, and for the use and benefit of its successors and assigns, to the full end of the term for which Letters Patent may be granted as fully and entirely as the same would have been held by the Assignor had this assignment and sale not been made.

The undersigned hereby grant the firm of Benoit & Côté Inc., whose address is 560 Cremazie Blvd. East, Suite 300, Montreal, Quebec, H2P 1E8, Canada, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other Patent Offices in the world.

This assignment supersedes any previous assignments.

Les soussignés désirent que la présente cession soit en anglais. The undersigned request that the present assignment be in English.



G2204CA00

- 3 -

SIGNED this 9 day of June, 2020 at Edmonton, Canada
(City, Country)

ONCOQUEST INC.

By [Signature]

Name R. MADHAYAGAN

Title CEO

[Signature]

Signature of Witness

Thomas Woo

Name of Witness

G2204CA00

- 4 -


SIGNED this 12 day of June, 2020, at Seoul, Korea
(City, Country)


ONCOQUEST PHARMACEUTICALS INC.

By LEE

Name CHANG HYUN

Title CEO


Signature of Witness


Name of Witness



SCHEDULE A

<u>Country</u>	<u>Serial Number</u>	<u>Filing Date / Issue Date</u>
United States	6,716,966	April 6, 2004
United States	7,147,850	December 12, 2006
United States	6,689,355	February 10, 2004
Australia	2002358246	June 12, 2008
Canada	2,464,947	May 22, 2012
Switzerland	696871	January 15, 2008
United Kingdom	2397018	May 31, 2006
United States	8,038,994	October 18, 2011
United States	6,241,985	June 5, 2001
United States	8,945,566	February 3, 2015
United States	8,697,079	April 15, 2014
Europe	2331130	February 14, 2018
France	2331130	February 14, 2018
United Kingdom	2331130	February 14, 2018
WO	PCT/CA2015/050747	August 7, 2015
China	201580053422.8	August 7, 2015
Europe	15829910.7	August 7, 2015
Japan	2017-526729	August 7, 2015
United States	10,392,444	August 27, 2019
United States	16/448,453	June 21, 2019
United States	62/034,915	August 8, 2014
WO	PCT/CA2016/050035	January 15, 2016



G2204CA00

- 6 -

China	201680006115.9	January 15, 2016
Europe	16737010.5	January 15, 2016
Japan	2017-537509	January 15, 2016
United States	15/541,451	January 15, 2016
United States	62/103,758	January 15, 2015
WO	PCT/CA2018/050095	January 26, 2018
China	2018800105245	January 26, 2018
Canada	3,051,913	January 26, 2018
Europe	17164584.9	April 3, 2017
Japan	2017-075356	April 5, 2017
United States	10,537,636	January 21, 2020
United States	16/702,323	December 3, 2019
United States	62/455,114	February 6, 2017
WO	PCT/CA2017/050901	July 27, 2017
United States	16/482,163	July 30, 2019
United States	15/470,733	March 27, 2017

